Axcella Health Past Earnings Performance
Past criteria checks 0/6
Axcella Health's earnings have been declining at an average annual rate of -9.8%, while the Biotechs industry saw earnings growing at 17.4% annually.
Key information
-9.8%
Earnings growth rate
46.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Axcella Therapeutics drops 9% on $34.2M stock offering
Oct 13Axcella adds 20% as mid-stage trial indicates potential of NASH therapy
Sep 29Axcella Health GAAP EPS of -$0.40 misses by $0.02
Aug 12Axcella Health: Revisiting A Lottery Ticket
Apr 25Axcella Health EPS beats by $0.01
May 06Have Insiders Been Buying Axcella Health Inc. (NASDAQ:AXLA) Shares This Year?
Feb 19
Axcella decides not to expand enrollment in AXA4010-001 following cohort 1 readout
Jan 11Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?
Dec 28
Revenue & Expenses BreakdownBeta
How Axcella Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -48 | 12 | 29 |
| 31 Mar 23 | 0 | -66 | 13 | 45 |
| 31 Dec 22 | 0 | -81 | 16 | 57 |
| 30 Sep 22 | 0 | -76 | 17 | 56 |
| 30 Jun 22 | 0 | -74 | 18 | 53 |
| 31 Mar 22 | 0 | -68 | 20 | 46 |
| 31 Dec 21 | 0 | -65 | 19 | 43 |
| 30 Sep 21 | 0 | -62 | 18 | 41 |
| 30 Jun 21 | 0 | -59 | 17 | 39 |
| 31 Mar 21 | 0 | -57 | 17 | 37 |
| 31 Dec 20 | 0 | -57 | 17 | 37 |
| 30 Sep 20 | 0 | -57 | 16 | 39 |
| 30 Jun 20 | 0 | -62 | 16 | 44 |
| 31 Mar 20 | 0 | -62 | 16 | 44 |
| 31 Dec 19 | 0 | -59 | 16 | 42 |
| 30 Sep 19 | 0 | -53 | 14 | 37 |
| 30 Jun 19 | 0 | -45 | 12 | 31 |
| 31 Mar 19 | 0 | -40 | 10 | 28 |
| 31 Dec 18 | 0 | -36 | 8 | 25 |
Quality Earnings: AXLA is currently unprofitable.
Growing Profit Margin: AXLA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AXLA is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare AXLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: AXLA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.